Denmark

Denmark is a country which is considered to be one of the most economically and socially developed countries in the world. The official language is Danish.

The healthcare system in Denmark is universal and based on the principals of free and equal access to healthcare for all citizens. High-quality services are offered in the healthcare system, the majority of which are financed by general taxes.​

Healthcare budget

$27 billion

Inhabitants

5,6 million

GDP per capita

$60.556

Currency

DKK (1 DKK = 0,13 Euro)

World Ranking

GDP 39th

Danish healthcare

The healthcare in Denmark is rated as number four by EuroHealth Consumer Index 2018.

The Danish healthcare system is particularly distinguished in the areas of patient rights and information.

The Medicines Statistics Register (LSR) contains information on all sales and deliveries of medicines. Both what is sold in the pharmacy and in the stores, and what is delivered by the doctor or in the hospital. The Pharmaceutical Statistics Register is unique worldwide, as it is the only register of drug consumption that covers an entire country's population over so many years. In 2018, the industry spent $ 11,5 billion. DKK on research in Denmark. This makes Denmark the country that invests most in private drug research and development (only surpassed by Switzerland). And this makes the pharmaceutical industry the industry in Denmark that is most research-heavy. In 2018, we had exports of $ 100 billion DKK.

In 2017, $ 183 billion DKK went to the health care system. This corresponds to 16,4% of total public expenditure. In popular terms, this means that for every DKK 1.000 you pay in taxes, DKK 164 goes to health care.

Pharmaceutical environment

The Medicines Statistics Register (LSR) contains information on all sales and deliveries of medicines. Both what is sold in the pharmacy and in the stores, and what is delivered by the doctor or in the hospital.

The Pharmaceutical Statistics Register is unique worldwide, as it is the only register of drug consumption that covers an entire country's population over so many years.

In 2018, the industry spent $ 11,5 billion. DKK on research in Denmark. This makes Denmark the country that invests most in private drug research and development (only surpassed by Switzerland). And this makes the pharmaceutical industry the industry in Denmark that is most research-heavy. In 2018, we had exports of $ 100 billion DKK.

Denmark has also made dramatic advancement in the reduction of heart disease mortality in recent years.

Today’s challenges

There will be more senior citizens and the number of multi-illnesses will increas. This will cause a significantly rise in the cost of pharmaceuticals over the next years.

Another challenges, that has already been seeing, is a tightening of access to healthcare for the Danish patients. There is only acces to their own GP, or to the hospital.

This has already caused a higher demands on health care and at increased pressure on the healthcare system.

This in turn has made access to visits the doctors more difficult and less.

The Danish experts

Henrik Alfredsson & Clas Lindbergson

Challenge us with your case and we will show you the possibilities for your product.

Services

Sales and Marketing

Entering the European market is not easy. 27 countries with different healthcare systems. What is your strategy? Apart from the Big-5, what do you do with the other 22 countries? We offer a solution for 11 countries. Sales and marketing is our core business.

Learn more

Distribution

We manage, through our logistic partners with their regional warehouses, the distribution to our region (11 countries). They have the capability to handle the most demanding of specialized product order management, storage, handling and distribution requirements.

Learn more

Early Market Research

You know that market research is critical. It provides customer insights, competitive intelligence, behavioural tendencies, and product positioning. And market research increasingly is becoming an important component for linking R&D and marketing teams.

Learn more

Market Access

Achieving reimbursement and getting the right price are the 2 most important drivers for a successful launch of an innovative pharmaceuticals in our part of Europe. Health Authorities in any European country decide individually based on their local regulations, policies, framework, social values and available health care budget.

Learn more

Market Authorisation

Unlike other regions, in the EU a number of options is available to obtain a marketing authorisation. Centralised at the European Medicines Agency in Amsterdam or decentralised with the individual competent authorities of the member states, each marketing authorisation application procedure has its pros and cons.

Learn more

Pharmacovigilance

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.

Learn more